VBI Vaccines Reports Third Quarter 2023 Financial Results
PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023
Continued execution across earlier-stage pipeline, including:
Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients
Interim Phase 1 data announced for pan-coronavirus candidate, VBI-2901
Novel mRNA-launched eVLP platform technology announced
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.
"In Q3, we were focused on pip
